ArticleProceedings of the National Academy of Sciences of the United States of America2024
Charge barriers in the kidney elimination of engineered nanoparticles.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Hit the bull's eye: Engineered extracellular vesicles for targeted therapy.Bioactive materials · 2026Review
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- Nucleic acid sensing pathways in kidney disease development.Nature reviews. Nephrology · 2026Review
- Application-Driven Modular Design of Gold Nanoclusters for In Vivo Fluorescence Imaging.Small methods · 2026Review
- A Renally Excretable Gold Nanoparticle Oncology Platform Enabling Effective Photothermal Therapy and Chemotherapy Combination.ACS nano medicine · 2026Article
- Quantitative Assessment of Particulate Matter Biodistribution UsingEnvironmental science & technology · 2026Article
- Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms.International journal of nanomedicine · 2026Review
- Kidney-targeted nanoplatforms: Strategies and applications.Theranostics · 2026Review
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
- Breast Cancer Progression and Its Theranostic Management via Folate-Directed Targeting of Glycoprotein Receptor.Medical sciences (Basel, Switzerland) · 2025Review
- Reno-protective CT contrast nanoagent targets proximal tubular epithelium for kidney disease imaging and repair in a mouse model.Nature communications · 2025Article
- pH-Responsive Self-Assembly of Renal-Clearable Nanoparticles in the Kidneys: One Assembly per Endosome.Journal of the American Chemical Society · 2025Article
- Blood Retention and Kidney Clearance of Renal-Clearable Gold Nanoparticles Strongly Correlate with Renal Injury Biomarkers.Angewandte Chemie (International ed. in English) · 2025Article
- Mass Spectrometry Imaging Reveals That Gold Nanomaterial Surface Chemistry Affects Transport and Excretion in Mice over Time.Chemical & biomedical imaging · 2025Article
- Cellular determinants influence the red blood cell adsorption efficiency of poly(amine-Science advances · 2025Article
- Design Considerations for Organ-Selective Nanoparticles.ACS nano · 2025Review
- Nanoparticle Transport in Proximal Tubules with Rhabdomyolysis-Induced Necrosis.Angewandte Chemie (International ed. in English) · 2025Article
- Inorganic Nanoparticles Containing Plant-Derived Compounds for Kidney Treatment.Bioinorganic chemistry and applications · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The renal elimination pathway is increasingly harnessed to reduce nonspecific accumulation of engineered nanoparticles within the body and expedite their clinical applications. While the size of nanoparticles is recognized as crucial for their passive filtration through the glomerulus due to its limited pore size, the influence of nanoparticle charge on their transport and interactions within the kidneys remains largely elusive. Herein, we report that the proximal tubule and peritubular capillary, rather than the glomerulus, serve as primary charge barriers to the transport of charged nanoparticles within the kidney. Employing a series of ultrasmall, renal-clearable gold nanoparticles (AuNPs) with precisely engineered surface charge characteristics as multimodal imaging agents, we have tracked their distribution and retention across various kidney components following intravenous administration. Our results reveal that retention in the proximal tubules is governed not by the nanoparticle's zeta-potential, but by direct Coulombic interactions between the positively charged surface ligands of the AuNPs and the negatively charged microvilli of proximal tubules. However, further enhancing these interactions leads to increased binding of the positively charged AuNPs to the peritubular capillaries during the initial phase of elimination, subsequently facilitating their slow passage through the glomeruli and interaction with tubular components in a charge-selective manner. By identifying these two critical charge-dependent barriers in the renal transport of nanoparticles, our findings offer a fundamental insight for the design of renal nanomedicines tailored for selective targeting within the kidney, laying down a foundation for developing targeting renal nanomedicines for future kidney disease management in the clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.